Drug Trial Radar · NCT03962738
A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
846
Actual
Start
May 31, 2019
Primary completion
Jun 8, 2020
Study completion Jun 8, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.
Conditions
- Migraine
Interventions
LasmiditanDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Are Headache Pain Free In High Dose Group (200 mg Lasmiditan)Time frame: 2 Hours Postdose
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Doi Clinic Internal Medicine Neurology
Hiroshima, Japan
Tanaka neurosurgical clinic
Kagoshima, Japan
Umenotsuji Clinic
Kochi, Japan
Kumamoto City Hospital
Kumamoto, Japan
Tatsuoka Neurology Clinic
Kyoto, Japan
Ishikawa Clinic
Kyoto, Japan
Osaka Saiseikai Nakatsu Hospital
Osaka, Japan
Tominaga Hospital
Osaka, Japan
Japanese Red Cross Shizuoka Hospital
Shizuoka, Japan
Takanoko Hospital
Matsuyama, Ehime, Japan
Ikeda Neurosurgical Clinic
Kasuga-shi, Fukuoka, Japan
Jinnouchi Neurosurgery Clinic
Kasuga-shi, Fukuoka, Japan
SUBARU Health Insurance Society Ota Memorial Hospital
Ota-shi, Gunma, Japan
Nakamura Memorial Hospital
Sapporo, Hokkaido, Japan
Kohnan Hospital
Kobe, Hyōgo, Japan
Nishinomiya Municipal Central Hospital
Nishinomiya, Hyōgo, Japan
Yamaguchi Clinic
Nishinomiya-shi, Hyōgo, Japan
Fujitsu Clinic
Kawasaki, Kanagawa, Japan
Sendai Headache and Neurology Clinic
Sendai, Miyagi, Japan
Okayama City General Medical Center Okayama City Hospital
Okayama, Okayama-ken, Japan
Chibune General Hospital
Osaka, Osaka, Japan
Takase internal medicine clinic
Toyonaka-shi, Osaka, Japan
Osoegawa Neurology Clinic
Saga, Saga-ken, Japan
Saitama Medical University Hospital
Iruma-Gun, Saitama, Japan
Saitama Neuropsychiatric Institute
Saitama, Saitama, Japan
Saino Clinic
Tokorozawa, Saitama, Japan
Dokkyo Medical University Hospital
Shimotsuga-Gun, Tochigi, Japan
Niwa Family Clinic
Chofu-shi, Tokyo, Japan
Sanno Clinic Shinagawa
Minato-ku, Tokyo, Japan
USUDA CLINIC for internal medicine
Setagaya-ku, Tokyo, Japan
Tokyo Headache Clinic
Shibuya-ku, Tokyo, Japan
Fukuuchi Pain Clinic
Shinjuku-ku, Tokyo, Japan
Sakura Clinic Internal Medicine Neurology
Toyama, Toyama, Japan
Nagaseki Headache Clinic
Kai-Shi, Yamanashi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.